Determination of Content of Recombinant Human Interferon α1b Dry Powder Inhalation by HPLC

LIU A-Na, ZHOU Min-Yi, SONG Wen-Jin, LIU Jian-Beng

China Biotechnology ›› 2010, Vol. 30 ›› Issue (05) : 92-95.

PDF(428 KB)
PDF(428 KB)
China Biotechnology ›› 2010, Vol. 30 ›› Issue (05) : 92-95.

Determination of Content of Recombinant Human Interferon α1b Dry Powder Inhalation by HPLC

  • LIU A-na1,2,ZHOU Min-yi2,SONG Wen-jin2,LIU Jian-ping1
Author information +
History +

Abstract

A method for the determination of content and uniformity of recombinant human interferon α1b dry powder inhalation by HPLC was developed. A good linearity was obtained in the range of 92.50~462.50μg/ml(r=0.999 9).Good peak shape of interferon α1b was achieved. The impurities and flow phase have no interference to the interferon in this system. This method was approved to be precise, accurate, stable and rapid  for the determination of content of recombinant human interferon α1b in medicinal product.

Key words

HPLC / Recombinant human interferon α1b / Dry powder inhalation / Content

Cite this article

Download Citations
LIU A-Na, ZHOU Min-Yi, SONG Wen-Jin, LIU Jian-Beng. Determination of Content of Recombinant Human Interferon α1b Dry Powder Inhalation by HPLC[J]. China Biotechnology, 2010, 30(05): 92-95

References

[1] 侯云德.分子病毒学.北京:学苑出版社,1990,598599. Hou Y D.Molecular Virology.Beijing: Academy Press,1990,598599. 
[2] 中国药典(三部).北京:中国医药科技出版社,2010,附录ⅩC. ChP(Vol Ⅲ) .Beijing:China Medical Science and Technology Press,2010,Appendix ⅩC. 
[3] HakKim C,Andy C,Igor G,et al .Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.pharmaceutical research,1997 ,4(14):431437. 
[4] Hiroaki T,Hirokazu O,Kotaro I,et al.Improvement of stability and absorbability of dry insulin powder for inhalation by powderconbination technique.International Journal of Pharmaceutics,2004,3(271):4152. 
[5] YuhFun M,PhuongAnh N,Theresa S,et al.Protein inhalation powders: spray drying vs spray freeze drying.Pharmaceutical Research,1999,2(16):249254. 
[6] 那伊.蛋白质药物开发与生产.北京:化学工业出版社,2006,28. Na Y.Protein DrugsDevelopment and Production.Beijing: Chemical Industry Press,2006,28. 
[7] 吴美英,曹艳,孙俭波.应用高效液相色谱法定量检测重组人干扰素alb.中国生物制品学杂,2003,16(3):175176. Wu M Y,Cao Y,Sun J B.Chinese Journal of Biologicals,2003,16(3):175176. 
[8] 陈勇,陈妍.重组干扰素α1b壳聚糖涂膜剂的制备及质量控制.中国药房,2006,17(1):2728. Chen Y,Chen Y.China Pharmacy,2006,17(1):2728. 
[9] 中国药典(二部).北京:中国医药科技出版社,2010,附录ⅠL. ChP(Vol Ⅱ) .Beijing:China Medical Science and Technology Press,2010,Appendix ⅠL. 
[10] 国家食品药品监督管理局吸入制剂质量控制研究技术指导原则2007,124. SFDA. Guidance on the quality control of inhalation products2007,124.

PDF(428 KB)

321

Accesses

0

Citation

Detail

Sections
Recommended

/